Biopharma SHAKTI commits Rs. 10,000 crore to scale biologics manufacturing, translational research, and supply chains over five years, a strategic bet on biosimilars, advanced therapies, and domestic capacity. The fund aims to foster industry-academia incubators, incentives for advanced production, and a stronger export orientation. If executed, the scheme could reduce import dependence, lower therapy costs, and attract global investment into India’s next-generation drug industry. This measure requires clear timelines and state-level coordination.
Trending
- The Complete August 2026 Social Security Payment Schedule
- Meet the therapy pig helping DC’s homeless
- American Indian Schools Achieve Highest Graduation Rates in the Nation’s History
- The Social Security Decision Millions Make When They Turn 65 – And Why It Often Costs Them
- The Entrepreneur’s Guide to Designing a Custom Engagement Ring
- Social Security’s 2027 COLA: There’s Good News and Bad for Retirees
- 81 Best Compliments for Teachers That Praise Their Efforts
- New Zealand Rugby Throws Support Behind Mitey’s 2026 Campaign For Young Kiwis’ Mental Wellbeing
Tuesday, July 28
